Table 2.
Morbidity characteristics of participants residing in Edmonton, Alberta during the April 2008 to March 2009 fiscal year
| Prevalence, % | |||||
|---|---|---|---|---|---|
| Characteristic | Final algorithm | Using hospitalizations, claims, and ACCS | Using only hospitalizations and claims | Using only hospitalizations and ACCS | Using only hospitalizations |
| Number of morbidities | |||||
| One | 23.3 | 24.0 | 23.9 | 12.0 | 6.9 |
| Two | 11.5 | 12.1 | 11.9 | 4.9 | 3.7 |
| Three | 5.6 | 6.0 | 5.8 | 2.5 | 2.1 |
| Four | 2.8 | 3.1 | 2.9 | 1.4 | 1.1 |
| Five or more | 3.4 | 3.7 | 3.4 | 1.8 | 1.4 |
| Morbidities | |||||
| Alcohol misuse | 2.4 | 2.8 | 2.4 | 2.4 | 1.8a |
| Asthma | 2.3 | 6.9 | 6.8 | 2.3 b | 2.0b |
| Atrial fibrillation | 2.4 | 2.5 | 2.4 | 1.9 | 1.6a |
| Cancer, lymphoma | 0.2 | 0.2 | 0.2 | 0.1a | 0.1a |
| Cancer, metastatic | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 |
| Cancer, non-metastatic | 2.2 | 2.2 | 2.2 | 1.1b | 1.0b |
| Chronic heart failure | 2.5 | 2.6 | 2.5 | 1.6a | 1.4a |
| Chronic kidney disease1 | 20.8 | 3.8 (20.9) | 3.6 (20.8) | 2.9 (20.4) | 2.2 (20.1)a |
| Chronic pain | 6.5 | 6.5 | 5.2 | 1.4b | 0.1b |
| Chronic pulmonary disease | 7.0 | 7.2 | 7.0 | 2.7b | 2.3b |
| Chronic viral hepatitis B | 0.1 | 0.1 | 0.1 | 0.1b | <0.1b |
| Cirrhosis | 0.2 | 0.2 | 0.1 | 0.1 | 0.1a |
| Dementia | 1.6 | 1.6 | 1.6 | 1.1a | 0.9a |
| Depression | 8.7 | 8.9 | 8.7 | 1.7b | 1.0b |
| Diabetes | 8.8 | 8.9 | 8.8 | 5.6a | 3.1b |
| Epilepsy | 1.4 | 1.4 | 1.2 | 0.7b | 0.1b |
| Hypertension | 22.8 | 23.0 | 22.8 | 8.8b | 7.8b |
| Hypothyroidism | 7.6 | 7.6 | 7.6 | 2.3b | 2.2b |
| Inflammatory bowel disease | 1.0 | 1.1 | 1.0 | 0.7a | 0.2b |
| Irritable bowel syndrome | 1.9 | 2.0 | 1.9 | 0.6b | 0.4b |
| Multiple sclerosis | 0.7 | 0.8 | 0.7 | 0.4a | 0.1b |
| Myocardial infarction | 1.7 | - | - | - | 1.7 |
| Parkinson’s disease | 0.5 | 0.5 | 0.5 | 0.3b | 0.2b |
| Peptic ulcer disease | 0.2 | 0.2 | 0.2 | 0.1a | 0.1b |
| Peripheral vascular disease | 0.7 | 0.7 | 0.6 | 0.3b | 0.2b |
| Psoriasis | 0.9 | 1.0 | 0.9 | 0.2b | 0.1b |
| Rheumatoid arthritis | 1.5 | 1.6 | 1.5 | 0.8a | 0.5b |
| Schizophrenia | 1.5 | 1.5 | 1.5 | 0.7b | 0.6b |
| Severe constipation | 0.6 | 0.7 | 0.6 | 0.4a | 0.3b |
| Stroke or transient ischemic attack | 4.2 | 4.2 | 3.8 | 2.4a | 0.9b |
aIndicate morbidities where removing a sources or sources resulted in prevalence reduced between 25 to 50% compared to estimates using all three sources. bDemonstrates morbidities where prevalence was reduced >50% compared to all three sources.
The prevalence values in the first column and the bold prevalence values in the remaining columns are estimates from the final algorithms given in Table 1. The bolded prevalence values indicate which administrative datasets were used in the final algorithms.
1Values in brackets include laboratory data (estimated glomerular filtration rate and albuminuria) as gold standard measures of kidney function